X0306 4 2020-07-07 0 0001674416 CRISPR Therapeutics AG CRSP 0001682017 Novak Rodger C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 1 1 0 0 President Common Shares 2020-07-07 4 M 0 5586 1.81 A 653593 D Common Shares 2020-07-07 4 M 0 19414 14.00 A 673007 D Common Shares 2020-07-07 4 S 0 25000 90.00 D 648007 D Stock Option (Right to Buy) 1.81 2020-07-07 4 M 0 5586 0.00 D 2025-09-10 Common Shares 5586 0 D Stock Option (Right to Buy) 14.00 2020-07-07 4 M 0 19414 0.00 D 2026-10-18 Common Shares 19414 140826 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vesting in 31 equal monthly installments thereafter. This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule. /s/ Michael Esposito, attorney-in-fact 2020-07-09